• KOLs
  • Lung Cancer
  • Department Of Thoracic Surgery, Guangdong Esophag

Department of Thoracic Surgery, Guangdong Esophag: Influence Statistics

Department of Thoracic Surgery Guangdong: Expert Impact

Concepts for which Department of Thoracic Surgery Guangdong has direct influence: Lung cancer , Cell lung , Lung adenocarcinoma , Small cell , Atrial fibrillation , Esophageal cancer , Egfr mutation .

Department of Thoracic Surgery Guangdong: KOL impact

Concepts related to the work of other authors for which for which Department of Thoracic Surgery Guangdong has influence: Lung cancer , Small cell , Egfr mutations , Atrial fibrillation , Nsclc patients , Brain metastases , Gene expression .

KOL Resume for Department of Thoracic Surgery, Guangdong Esophag

Year

Prominent publications by Department of Thoracic Surgery, Guangdong Esophag

KOL-Index: 27816 . BACKGROUND: We aimed to assess the effect of afatinib on overall survival of patients with EGFR mutation-positive lung adenocarcinoma through an analysis of data from two open-label, randomised, phase 3 trials. METHODS: Previously untreated patients with EGFR mutation-positive stage IIIB or IV lung adenocarcinoma were enrolled in LUX-Lung 3 (n=345) and LUX-Lung 6 (n=364). These patients ...
Known for Lung 3 | Survival Data | Egfr Mutation | Afatinib Chemotherapy
KOL-Index: 24796 . Importance: Coronavirus disease 2019 (COVID-19) has resulted in considerable morbidity and mortality worldwide since December 2019. However, information on cardiac injury in patients affected by COVID-19 is limited. Objective: To explore the association between cardiac injury and mortality in patients with COVID-19. Design, Setting, and Participants: This cohort study was conducted from ...
Known for Cardiac Injury | Hospitalized Patients | Wuhan China | Median Iqr
KOL-Index: 23320 . BACKGROUND: Afatinib-an oral irreversible ErbB family blocker-improves progression-free survival compared with pemetrexed and cisplatin for first-line treatment of patients with EGFR mutation-positive advanced non-small-cell lung cancer (NSCLC). We compared afatinib with gemcitabine and cisplatin-a chemotherapy regimen widely used in Asia-for first-line treatment of Asian patients with ...
Known for 3 Trial | Egfr Mutation | Gemcitabine Cisplatin | Asian Patients
KOL-Index: 20844 . BACKGROUND: Activating mutations in EGFR are important markers of response to tyrosine kinase inhibitor (TKI) therapy in non-small-cell lung cancer (NSCLC). The OPTIMAL study compared efficacy and tolerability of the TKI erlotinib versus standard chemotherapy in the first-line treatment of patients with advanced EGFR mutation-positive NSCLC. METHODS: We undertook an open-label, randomised, ...
Known for Patients Chemotherapy | 3 Study | Advanced Egfr | Cell Lung
KOL-Index: 20681 . BACKGROUND: For patients with non-small-cell lung cancer (NSCLC) and multiple brain metastases, whole-brain irradiation (WBI) is a standard-of-care treatment, but its effects on neurocognition are complex and concerning. We compared the efficacy of an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), icotinib, versus WBI with or without chemotherapy in a phase 3 ...
Known for Multiple Brain Metastases | Icotinib Wbi | Cell Lung | Brain Irradiation
KOL-Index: 20586 . N6-methyladenosine (m6A) mRNA modifications play critical roles in various biological processes. However, no study addresses the role of m6A in macroautophagy/autophagy. Here, we show that m6A modifications are increased in H/R-treated cardiomyocytes and ischemia/reperfusion (I/R)-treated mice heart. We found that METTL3 (methyltransferase like 3) is the primary factor involved in aberrant ...
Known for M6a Modification | Mettl3 Tfeb | Rna Demethylase | Alkb Homolog
KOL-Index: 20168 . BACKGROUND: The irreversible ErbB family blocker afatinib and the reversible EGFR tyrosine kinase inhibitor gefitinib are approved for first-line treatment of EGFR mutation-positive non-small-cell lung cancer (NSCLC). We aimed to compare the efficacy and safety of afatinib and gefitinib in this setting. METHODS: This multicentre, international, open-label, exploratory, randomised ...
Known for Afatinib Gefitinib | Cell Lung | Controlled Trial | Patients Egfr
KOL-Index: 20016 . BACKGROUND: The phase 3 LUME-Lung 1 study assessed the efficacy and safety of docetaxel plus nintedanib as second-line therapy for non-small-cell lung cancer (NSCLC). METHODS: Patients from 211 centres in 27 countries with stage IIIB/IV recurrent NSCLC progressing after first-line chemotherapy, stratified by ECOG performance status, previous bevacizumab treatment, histology, and presence ...
Known for Nintedanib Docetaxel | Placebo Patients | Lung 1 | Adenocarcinoma Histology
KOL-Index: 19234 . Background: Co-administration of multiple antiemetics that inhibit several molecular pathways involved in emesis is required to optimize chemotherapy-induced nausea and vomiting (CINV) control in patients receiving highly emetogenic chemotherapy (HEC). NEPA, a fixed combination of a highly selective NK1 receptor antagonist, netupitant (300 mg), and the pharmacologically distinct 5-HT3RA, ...
Known for Highly Emetogenic Chemotherapy | Induced Nausea | Aprepitant Regimen | Apr Gran
KOL-Index: 19008 . BACKGROUND: Adjuvant chemotherapy after radical resection of stage IIIA non-small-cell lung cancer (NSCLC) has quite poor outcomes. We aimed to investigate whether adjuvant erlotinib therapy improves 2-year disease-free survival compared with chemotherapy in epidermal growth factor receptor (EGFR) mutation-positive stage IIIA NSCLC. METHODS: In this randomised, open-label, phase 2 trial, ...
Known for Adjuvant Therapy | Egfr Mutation | Stage Iiia | Cell Lung
KOL-Index: 18744 . The molecular mechanism underlying activation of matrix metallopeptidase 9 (MMP9) in non-small cell lung cancer (NSCLC) cells, which controls cancer invasiveness and metastasis, remains elusive. Here, we reported a strong correlation of epidermal growth factor receptor (EGFR) and MMP9 levels in NSCLC patients. Thus, we used a human NSCLC line, A549, to examine whether there is a causal ...
Known for Mmp9 Activation | Epidermal Growth Factor | Cell Lung | Retracted Article
KOL-Index: 18725 . BACKGROUND: First-line nivolumab plus ipilimumab has shown improved overall survival in patients with advanced non-small-cell lung cancer (NSCLC). We aimed to investigate whether the addition of a limited course (two cycles) of chemotherapy to this combination would further enhance the clinical benefit. METHODS: This randomised, open-label, phase 3 trial was done at 103 hospitals in 19 ...
Known for Chemotherapy Patients | Ipilimumab Cycles | 3 Trial | Cell Lung
KOL-Index: 18633 . BACKGROUND: Fewer than half of the patients with completely resected non-small-cell lung cancer (NSCLC) are cured. Since the introduction of adjuvant chemotherapy in 2004, no substantial progress has been made in adjuvant treatment. We aimed to assess the efficacy of the MAGE-A3 cancer immunotherapeutic in surgically resected NSCLC. METHODS: In this randomised, double-blind, ...
Known for 3 Trial | Placebo Patients | Adjuvant Therapy | Cancer Immunotherapeutic
KOL-Index: 18147 . Importance: Anlotinib is a novel multitarget tyrosine kinase inhibitor for tumor angiogenesis and proliferative signaling. A phase 2 trial showed anlotinib to improve progression-free survival with a potential benefit of overall survival, leading to the phase 3 trial to confirm the drug's efficacy in advanced non-small cell lung cancer (NSCLC). Objective: To investigate the efficacy of ...
Known for Anlotinib Patients | Small Cell | Advanced Nsclc | Phase 3
KOL-Index: 17808 . BACKGROUND: We evaluated the efficacy and safety of tepotinib, a potent and highly selective oral MET inhibitor, plus gefitinib in patients with epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) with MET overexpression (immunohistochemistry [IHC]2+ or IHC3+) or MET amplification having acquired resistance to EGFR inhibition. METHODS: In this open-label, ...
Known for Cell Lung | Chemotherapy Patients | Phase Tepotinib | Median Pfs

Key People For Lung Cancer

Top KOLs in the world
#1
Ahmedin M Jemal
united states breast cancer addis ababa
#2
Rebecca L Siegel
united states colorectal cancer incidence rates
#3
Freddie Ian Bray
cancer incidence nordic countries mortality rates
#4
Jacques Ferlay
cancer incidence global burden latin america
#5
Adi F Gazdar
lung cancer cell lines aberrant methylation
#6
Frances Alice Shepherd
lung cancer small cell adjuvant chemotherapy